We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+32.57%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$628M
AUM Growth
+$187M
Cap. Flow
+$205M
Cap. Flow %
32.59%
Top 10 Hldgs %
40.48%
Holding
169
New
52
Increased
19
Reduced
22
Closed
47

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$59.7M
2
NUVL
Nuvalent
NUVL
+$10.3M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$10.1M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.47M
5
IRON icon
Disc Medicine
IRON
+$8.52M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$14.4M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.5M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$7.11M
4
BLU
BELLUS Health Inc.
BLU
+$6.37M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.19M

Sector Composition

Rank Sector Weight
1 Healthcare 44.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
151
MacroGenics
MGNX
$233M
– –
-250,000
Closed -$1.79M
PTCT icon
152
CALL
PTC Therapeutics
PTCT
$6.18B
– –
-9,800
Closed -$475K
RCKTW icon
153
Rocket Pharmaceuticals Warrant
RCKTW
$320K
– –
-367,112
Closed -$60K
SAGE
154
DELISTED
Sage Therapeutics
SAGE
– –
-17,805
Closed -$747K
SRPT icon
155
Sarepta Therapeutics
SRPT
$1.64B
– –
-8,324
Closed -$1.07M
VKTX icon
156
Viking Therapeutics
VKTX
$3.88B
– –
-43,156
Closed -$719K
VTYX
157
DELISTED
Ventyx Biosciences
VTYX
– –
-65,000
Closed -$2.24M
XBI icon
158
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-100,000
Closed -$7.62M
XLV icon
159
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
– –
-27,469
Closed -$3.56M
ITCI
160
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-380,000
Closed -$20.6M
MORF
161
CALL
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-213,400
Closed -$8.03M
MORF
162
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-45,873
Closed -$1.73M
MRTX
163
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-33,100
Closed -$1.23M
SPPI
164
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-176,980
Closed -$133K
ISEE
165
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-213,521
Closed -$5.19M
BLU
166
DELISTED
BELLUS Health Inc.
BLU
– –
-885,334
Closed -$6.37M
RXDX
167
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-125,926
Closed -$13.5M
STSA
168
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-136,059
Closed -$95K
BLCM
169
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-448,101
Closed -$148K
3 4 5 6
7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Ikarian Capital held 169 positions worth $628M, up 42% from $441M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ikarian Capital deployed $205M of net new capital in Q2 2023, opening 52 new positions and adding to 19 existing holdings. Its largest new stake was ACELYRIN: 2,918,426 shares worth $61M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $7.11M trimmed.

  • Ikarian Capital's largest Q2 2023 buy was ACELYRIN: 2,918,426 shares worth $61M.
  • Ikarian Capital added most to Apellis Pharmaceuticals in Q2 2023, an estimated $2.92M increase.
  • Ikarian Capital's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $7.11M.
  • Ikarian Capital fully exited Immunovant in Q2 2023, selling an estimated $14.4M.
  • Ikarian Capital's ten largest holdings make up 40% of its $628M portfolio in Q2 2023.
  • Ikarian Capital opened 52 new positions and closed 47 in Q2 2023.
  • Ikarian Capital's portfolio value rose 42% quarter-over-quarter to $628M.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.